Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction
- Author(s)
- Boyle, S; Wellard, C; Moore, EM; Blacklock, H; Harrison, SJ; Ho, PJ; Hocking, J; McQuilten, ZK; Quach, H; Spearing, R; Wood, EM; Spencer, A; Mollee, P; Myeloma and Related Diseases Registry Investigators;
- Details
- Publication Year 2021-10,Volume 107,Issue #4,Page 497-499
- Journal Title
- European Journal of Haematology
- Publication Type
- Research article
- Keywords
- Bortezomib; Dexamethasone; Humans; Lenalidomide; *Multiple Myeloma/diagnosis/drug therapy
- Department(s)
- Haematology
- PubMed ID
- 34129711
- Publisher's Version
- https://doi.org/10.1111/ejh.13677
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-06-13 07:47:46
Last Modified: 2025-06-13 07:51:46